Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  RVXCF | T.RVX.W.A

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Recent & Breaking News (TSX:RVX)

Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer’s Disease (CTAD) Asia and Alzheimer’s Association International Conference (AAIC)

GlobeNewswire July 17, 2018

Hemostemix Formalizes World-Class Scientific Advisory Board

GlobeNewswire July 5, 2018

Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone

GlobeNewswire June 14, 2018

Resverlogix Announces Withdrawal of Public Offering of Units

GlobeNewswire June 8, 2018

Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the “Shock and Kill” Approach

GlobeNewswire June 7, 2018

Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress

GlobeNewswire May 24, 2018

Resverlogix Announces Lifting by TSX of Review

GlobeNewswire May 10, 2018

Resverlogix Closes US$30 Million Loan

GlobeNewswire May 7, 2018

Resverlogix Advances US$30 Million Loan Closing Documentation

GlobeNewswire May 1, 2018

Resverlogix Announces Proposed Offering of Units

GlobeNewswire April 17, 2018

Resverlogix Announces TSX Review Update

GlobeNewswire April 12, 2018

Resverlogix Announces US$30 Million Loan Commitment Letter

GlobeNewswire April 11, 2018

Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease

GlobeNewswire March 28, 2018

Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial

GlobeNewswire March 19, 2018

Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

GlobeNewswire February 26, 2018

Resverlogix Highlights Key Accomplishments and 2018 Targets

GlobeNewswire February 8, 2018

Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial

GlobeNewswire January 11, 2018

Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing Agreement

GlobeNewswire January 8, 2018

Resverlogix Announces Filing of Quarterly Financial Statements and Management’s Discussion & Analysis

GlobeNewswire December 14, 2017

Resverlogix Announces Voting Results From The 2017 Annual Meeting Of Shareholders

GlobeNewswire December 12, 2017